EyePoint Pharmaceuticals said it completed enrollment in both pivotal Phase 3 trials of DURAVYU for diabetic macular edema. Topline data are expected in Q4 2027

BWB News TV • 2026-07-30 11:16 UTC • By Billy Odell Tucker-Robinson

EyePoint Pharmaceuticals said it completed enrollment in both pivotal Phase 3 trials of DURAVYU for diabetic macular edema. Topline data are expected in Q4 2027, setting a long-dated catalyst for the ophthalmology developer.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly